(Total Views: 265)
Posted On: 10/31/2017 10:53:23 PM
Post# of 72443
Hmmm...top line is the mover information:
Great efficacy with endoscope images.
No SAEs.
Low systemic exposure numbers (far, far lower than B-ABSSSI).
Not sure what else the market would be looking at. All that stuff was highlighted in the presentations. Maybe a little more in depth PK data? The next big B-UP update I am expecting is either a partnership or a formulation update. B-OM will likely be where we go for the quick kill with a BTD or shoe-in phase 3.
Great efficacy with endoscope images.
No SAEs.
Low systemic exposure numbers (far, far lower than B-ABSSSI).
Not sure what else the market would be looking at. All that stuff was highlighted in the presentations. Maybe a little more in depth PK data? The next big B-UP update I am expecting is either a partnership or a formulation update. B-OM will likely be where we go for the quick kill with a BTD or shoe-in phase 3.
(0)
(0)
All my posts are my own personal opinion and speculation. They should not be used as the basis for any investment decision. No, I am not Scottsmith.
Scroll down for more posts ▼
